@Mason14
In Combination with DecitabineI’m very excited about the potential developments in combining Bisantrene with Decitabine for solid tumors. Due to IP restrictions influencing the amount of data RAC can report, I speculate that they are much more informed about this synergy and have been for some time. Discoveries like the Bisantrene IV formulation, cardioprotection MoA, and now this take a long time to establish patent coverage, thus it is my assumption that what we are seeing is relatively old news for them.
Makes sense that Dr T took half his salary in shares, if they were sitting on this would he not be prevented from buying on market himself? Or I'm I thinking wrong?
If so, very smart way to accumulate without being accused of inside trading.
- Forums
- ASX - By Stock
- RAC
- Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing
Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-66
-
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M |
Open | High | Low | Value | Volume |
$1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | $1.94 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.95 | 7574 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | 1.940 |
2 | 30000 | 1.900 |
1 | 4861 | 1.880 |
1 | 3000 | 1.850 |
1 | 30000 | 1.840 |
Price($) | Vol. | No. |
---|---|---|
1.950 | 7574 | 1 |
1.995 | 10037 | 1 |
2.000 | 8000 | 3 |
2.020 | 4000 | 1 |
2.040 | 2000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
RAC (ASX) Chart |